Early versus late stage schizophrenia. What markers make the difference?

被引:3
作者
Garcia-Alvarez, L. [1 ,2 ,3 ,4 ]
Garcia-Portilla, M. P. [1 ,2 ,3 ,4 ,5 ]
Caso, J. R. [2 ,6 ,7 ,8 ]
de la Fuente-Tomas, L. [2 ,3 ,4 ]
Gonzalez-Blanco, L. [3 ,5 ]
Saiz Martinez, P. [1 ,2 ,3 ,4 ,5 ]
Leza, J. C. [2 ,6 ,7 ,8 ]
Bobes, J. [1 ,2 ,3 ,4 ,5 ]
机构
[1] Fdn Invest & Innovac Biosanitaria Principado Astu, Oviedo, Spain
[2] Ctr Invest Biomed Red Salud Mental CIBERSAM, Oviedo, Spain
[3] Univ Oviedo, Fac Med, Area Psiquiatr, Oviedo, Spain
[4] Inst Neurociencias Principado Asturias INEUROPA, Oviedo, Spain
[5] SESPA, Serv Salud Principado Asturias, Oviedo, Spain
[6] UCM, Fac Med, Dept Farmacol, Madrid, Spain
[7] Inst Invest Sanitaria Hosp Ab Octubre Imasab, Madrid, Spain
[8] UCM, Inst Univ Invest Neuroquim, Madrid, Spain
关键词
Early-stage schizophrenia; late-stage schizophrenia; psychopathology; functioning; biomarkers; CONSENSUS COGNITIVE BATTERY; 1ST EPISODE; NEGATIVE SYMPTOMS; 1ST-EPISODE; OUTPATIENTS; DISORDERS; PSYCHOSIS; PREVALENCE; BIOMARKERS; PSYCHIATRY;
D O I
10.1080/15622975.2018.1511920
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objectives: To identify the psychopathological, cognitive, functional, physical health and inflammatory markers that differentiate between early-stage schizophrenia (ESSCH) and late-stage schizophrenia (LSSCH). Methods: Cross-sectional, naturalistic study of 104 patients with SCH. The sample was divided in two groups: 35 ESSCH (<= 7 years' duration of illness) and 69 LSSCH (>10 years' duration of illness). Statistical analysis: chi-square test and Student's t-test and ANCOVA (or Quade test) controlling for age, sex, BMI and number of cigarettes/day. Finally, a binomial logistic regression was made. Results: ESSCH show greater negative symptom severity (t = 2.465, p = 0.015), lower levels of I kappa B alpha (F = 7.644, p = 0.007), were more frequently classified as normal weight (40% vs 18.8%, p = 0.032) compared with LSSCH. The binomial logistic regression model included age (B = 0.127, p = 0.001) and I kappa B alpha (B = 0.025, p = 0.002) and accounted for 38.9% of the variance (model df =7, chi-square =41.841, p < 0.0001). Conclusions: Age and I kappa B alpha are the unique markers that differentiate between ESSCH patients whose duration of illness is less than 7 years and LSSCH patients. These results support the hypothesis of toxicity of episodes and highlight the importance of preventing new episodes.
引用
收藏
页码:159 / 165
页数:7
相关论文
共 34 条
  • [1] Patterns of premorbid functioning in first episode psychosis: relationship to 2-year outcome
    Addington, J
    Addington, D
    [J]. ACTA PSYCHIATRICA SCANDINAVICA, 2005, 112 (01) : 40 - 46
  • [2] Social functioning in individuals at clinical high risk for psychosis
    Addington, Jean
    Penn, David
    Woods, Scott W.
    Addington, Donald
    Perkins, Diana O.
    [J]. SCHIZOPHRENIA RESEARCH, 2008, 99 (1-3) : 119 - 124
  • [3] A comparative psychometric study of the Spanish versions with 6, 17, and 21 items of the Hamilton Depression Rating Scale
    Bobes, J
    Bulbena, A
    Luque, A
    Dal-Ré, R
    Ballesteros, J
    Ibarra, N
    [J]. MEDICINA CLINICA, 2003, 120 (18): : 693 - 700
  • [4] Prevalence of Negative Symptoms in Outpatients With Schizophrenia Spectrum Disorders Treated With Antipsychotics in Routine Clinical Practice: Findings From the CLAMORS Study
    Bobes, Julio
    Arango, Celso
    Garcia-Garcia, Margarida
    Rejas, Javier
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2010, 71 (03) : 280 - 286
  • [5] Cognition in young schizophrenia outpatients: Comparison of first-episode with multiepisode patients
    Braw, Yoram
    Bloch, Yuval
    Mendelovich, Shlomo
    Ratzoni, Gideon
    Gal, Gilad
    Harari, Hagai
    Tripto, Asaf
    Levkovitz, Yechiel
    [J]. SCHIZOPHRENIA BULLETIN, 2008, 34 (03) : 544 - 554
  • [6] Cognition and psychopathology in first-episode psychosis: are they related to inflammation?
    Cabrera, B.
    Bioque, M.
    Penades, R.
    Gonzalez-Pinto, A.
    Parellada, M.
    Bobes, J.
    Lobo, A.
    Garcia-Bueno, B.
    Leza, J. C.
    Bernardo, M.
    [J]. PSYCHOLOGICAL MEDICINE, 2016, 46 (10) : 2133 - 2144
  • [7] Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options
    Chue, Pierre
    Lalonde, Justine K.
    [J]. NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2014, 10 : 777 - 789
  • [8] Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
    Cleeman, JI
    Grundy, SM
    Becker, D
    Clark, LT
    Cooper, RS
    Denke, MA
    Howard, WJ
    Hunninghake, DB
    Illingworth, DR
    Luepker, RV
    McBride, P
    McKenney, JM
    Pasternak, RC
    Stone, NJ
    Van Horn, L
    Brewer, HB
    Ernst, ND
    Gordon, D
    Levy, D
    Rifkind, B
    Rossouw, JE
    Savage, P
    Haffner, SM
    Orloff, DG
    Proschan, MA
    Schwartz, JS
    Sempos, CT
    Shero, ST
    Murray, EZ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19): : 2486 - 2497
  • [9] Del Bello V, 2016, PSYCHIAT DANUB, V28, pS39
  • [10] Regulation of inflammatory pathways in schizophrenia: A comparative study with bipolar disorder and healthy controls
    Garcia-Alvarez, L.
    Caso, J. R.
    Garcia-Portilla, M. P.
    de la Fuente-Tomas, L.
    Gonzalez-Blanco, L.
    Saiz Martinez, P.
    Leza, J. C.
    Bobes, J.
    [J]. EUROPEAN PSYCHIATRY, 2018, 47 : 50 - 59